Skip to main content

Table 4 Univariate analysis of TILs and the hematologic parameters associated with DFS in each of the breast cancer subtypes

From: The prognostic and predictive value of tumor-infiltrating lymphocytes and hematologic parameters in patients with breast cancer

Variable Disease-free survival
HR+ HER2+ Triple-negative
HR (95% CI) p HR (95% CI) p HR (95% CI) p
AMC (high vs. low) 1.68 (0.52–5.45) 0.390 0.87 (0.27–2.74) 0.809 5.18 (1.08–24.94) 0.040*
ANC (high vs. low) 0.47 (0.15–1.43) 0.181 0.47 (0.15–1.47) 0.194 1.03 (0.28–3.85) 0.961
ALC (high vs. low) 0.26 (0.08–0.83) 0.024* 0.56 (0.18–1.77) 0.323 0.34 (0.07–1.63) 0.177
NLR (high vs. low) 1.06 (0.36–3.17) 0.911 0.82 (0.26–2.54) 0.729 2.54 (0.63–10.15) 0.188
LMR (high vs. low) 0.13 (0.03–0.59) 0.008* 1.14 (0.36–3.58) 0.828 0.23 (0.05–1.11) 0.067
PLR (high vs. low) 0.87 (0.29–2.59) 0.801 1.08 (0.34–3.42) 0.892 1.49 (0.40–5.56) 0.551
CD8 (high vs. low) 0.91 (0.30–2.71) 0.860 0.65 (0.19–2.19) 0.483 2.75 (0.69–10.99) 0.153
FOXP3 (high vs. low) 0.78 (0.26–2.34) 0.664 0.78 (0.25–2.43) 0.664 1.41 (0.38–5.27) 0.608
  1. AMC absolute monocyte count, ALC absolute lymphocyte count, ANC absolute neutrophil count, LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, FOXP3 forkhead box protein 3, HER2+ hormone receptor positive or negative/ HER2-positive, HR+ hormone receptor positive/HER2-negative
  2. *p < 0.05